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were chosen for validation. Intense
pruritus is another major feature of
AD. The pathogenesis of cutaneous
pruritus is not well understood, but
it is thought to be induced by the
various products from the inflammatory
effector cells, including neuropeptides,
histamine, leukotrienes, and proteolytic
enzymes. The prolyl endopeptidase and
cathepsin B might be genes responsible
for producing the inflammatory agents.
Finally, coxsackie virus and adenovirus
receptor and delta sleep inducing pep-
tide are genes that were found repeat-
edly in the SSH library and their
expression levels were confirmed. Five
genes showed increased expression
levels in the AD samples compared
to normal control samples (Figure 1).
The coxsackie virus and adenovirus
receptor, prolyl endopeptidase, delta
sleep inducing peptide, and sphingo-
sine-1-phosphate lyase genes showed
markedly increased expression levels
in the AD samples compared to the
normal and psoriasis samples, but
their expression levels in the psoriasis
samples were lower than in the normal
control samples. CTBS was the only
gene that had a greater expression in
the psoriasis samples than in the AD
and normal samples (Figure 1).
In conclusion, this study was the
first attempt to identify differentially
expressed genes in lesional AD skin to
help increase our understanding of AD
with its complicated disease mechan-
ism. Although the known and unknown
genes found by using the SSH method
may be helpful in understanding the
complicated atopic pathophysiology,
there is a drawback that we used only
one normal sample. However, among
the 5 genes that were examined at the
transcription level, sphingosine-1-phos-
phate lyase, coxsackie virus and ade-
novirus receptor, prolyl endopeptidase,
and delta sleep inducing peptide are
genes that have not yet been studied for
the other skin diseases as well as AD.
Therefore, besides the known factors,
these genes are thought to provide an
important clue in analyzing the com-
plex mechanism of dry skin and itching.
In recent years, single-nucleotide poly-
morphism studies have made active
progress to grasp the individual genetic
causes of AD. However, most of the
studies focused on the known genes.
Thus, we adopted several tools to cover
as many genes as possible and comple-
ment the significance of the selected
genes with the SSH method. We are
currently in progress on an SNP study
centering on the genes included in the
SSH library. We hope that the selected
genes can be used for the treatment and
diagnosis of this common allergic skin
disease.
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TO THE EDITOR
Cutaneous T-cell-attracting chemokine
(CTACK), also called CCL27, belongs to
the CC chemokine family and is a ligand
for CC chemokine receptor (CCR) 10. It is
selectively and constitutively produced in
skin by epidermal keratinocytes (Morales
et al., 1999) and displayed on the surface
of dermal endothelial cells (Homey et al.,
2002). It selectively attracts cutaneous
lymphocyte antigen positive, CCR10-
positive memory T cells into inflamma-
tory sites (Morales et al., 1999). We and
other researchers previously reported that
serum levels of this chemokine reflect
disease activity of atopic dermatitis
(Kakinuma et al., 2003a; Hijnen et al.,
2004; Hon et al., 2004).
Abbreviations: CCR, CC chemokine receptor; CTACK, cutaneous T-cell-attracting chemokine;
CTCL, cutaneous T-cell lymphoma; MF, mycosis fungoides; TBI, tumor burden index
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CTACK/CCL 27 in CTCL
Mycosis fungoides (MF) and Sezary
syndrome are common types of cuta-
neous T-cell lymphoma (CTCL) (Will-
emze et al., 2005). CCR4 and CCR10
are expressed on tumor cells of MF and
Sezary syndrome (Ferenczi et al., 2002;
Notohamiprodjo et al., 2005). We
previously reported that serum levels
of thymus and activation-regulated
chemokine/CCL17, a ligand of CCR4,
reflect disease activity of MF (Kakinuma
et al., 2003b). However, there has been
no report of serum CTACK/CCL27
levels in patients with CTCL. This
prompted us to investigate the relation-
ship between CTACK/CCL27 and
CTCL.
Twenty-eight patients with CTCL (25
MF cases and three Sezary syndrome
cases) (mean7SD age: 59.7714.5
years), and 25 control subjects
(49.4721.0 years) were enrolled in this
study. The medical ethical committee
of the University of Tokyo approved all
described studies and the study was
conducted according to the Declaration
of Helsinki Principles. Informed con-
sent was obtained to use sera from
patients and controls. All patients with
CTCL were given diagnoses according
to WHO-EORTC classification for cu-
taneous lymphomas (Willemze et al.,
2005). Disease extent was classified
with types of skin lesions (patch, plaque,
tumor, and erythroderma) and tumor
burden index (TBI) (Schmid et al., 1999).
TBI is calculated as follows; TBI¼ 1þ
(patches2)þ (plaques 2)þ (tumor
1.3), where the patches factor equals 0 if
30% or less of the skin area is involved
and 1 if 430% of the skin area is
involved, and where the plaque or
tumor factor equals 1 if plaques or
tumors are present. In two MF patients
and three Sezary syndrome patients, we
collected the sera before and after
treatment. The 25 healthy controls had
no history of allergy, psoriasis, or CTCL.
All sera were stored at 201C until use.
CTACK/CCL27 immunoassay kits were
from R&D systems (Minneapolis,
MN). Serum levels of CTACK/CCL27
were measured as previously described
(Kakinuma et al., 2003a). Data obtained
from the ELISA are presented as
mean7SD. Data were analyzed using
Mann–Whitney’s U-test and paired
t-test. Correlation coefficients were de-
termined by using the Spearman’s rank
correlation test. A P-value o0.05 was
considered statistically significant.
The serum CTACK/CCL27 levels of
patients with CTCL were 1036.47
558.3 pg/ml, which was significantly
higher than those of controls
(651.67291.1 pg/ml, Po0.01). In
CTCL with patch (n¼15), plaque
(n¼5), tumor (n¼ 5), or erythroderma
(n¼3), the serum CTACK/CCL27 levels
were 719.67357.8, 1030.57322.3,
1724.67658.6, and 1333.37471.5 pg/
ml, respectively (Figure 1a). The levels
of patients with plaque and tumor were
significantly higher than those of con-
trols (Po0.05 and 0.001, respectively).
The levels of patients with tumor were
significantly higher than those of pa-
tients with patch or plaque (Po0.005
and 0.05, respectively). In five patients
with CTCL (three males and two
females, age ranged from 42 to 73
years), we measured serum CTACK/
CCL27 levels before and after treat-
ment. Two of them are MF with tumor,
and the others are Sezary syndrome.
Topical and oral corticosteroids, UV
phototherapy, electron beam, oral etre-
tinate, and/or systemic interferon gam-
ma were used. All cases, at least
temporarily, showed clearance of skin
lesions. The serum CTACK/CCL27 le-
vels significantly decreased from
1672.37746.8 to 553.97264.8 pg/ml
after treatment in accordance with the
improvement of skin conditions
(Po0.01, Figure 1b).
We next compared serum CTACK/
CCL27 levels with other clinical or
laboratory data: age, TBI, serum lactate
dehydrogenase, IgE, soluble interleukin
2 receptor, thymus and activation-regu-
lated chemokine/CCL17 levels, and
numbers of eosinophil and white blood
cell in peripheral blood. The serum
CTACK/CCL27 levels were significantly
correlated with TBI (r¼ 0.64, Po0.005)
(Figure 2a), the serum soluble IL-2
receptor, and thymus and activation-
regulated chemokine/CCL17 levels
(r¼0.72, Po0.005; r¼ 0.40, Po0.05,
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Figure 1. Serum CTACK/CCL27 levels. (a) Serum CTACK/CCL27 levels in patients with CTCL and in
healthy controls. Patients were divided based on types of skin lesions. Data are presented as mean7SD.
(b) Serum CTACK/CCL27 levels before and after successful treatment of CTCL.
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Figure 2. Correlation coefficient between serum CTACK/CCL27 levels and TBI. (a), serum soluble IL-2
receptor levels (b) or serum thymus and activation-regulated chemokine/CCL17 levels (c) in patients with
CTCL.
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CTACK/CCL 27 in CTCL
respectively) (Figure 2b and c). Other
factors were not correlated with serum
CTACK/CCL27 levels (data not shown).
In this study, we showed that serum
CTACK/CCL27 levels in patients with
CTCL strongly correlated with types of
skin lesions, TBI, serum soluble IL-2
receptor, and thymus and activation-
regulated chemokine/CCL17 levels, all
of which are already reported to be
good makers of disease activity (Wasik
et al., 1996; Schmid et al., 1999;
Kakinuma et al., 2003b). In addition,
serum CTACK/CCL27 levels in patients
with CTCL decreased after treatment.
This is the first report describing the
relationship between CTACK/CCL27
and CTCL. CTACK/CCL27 is expressed
at a small amount even in normal skin
(Kakinuma et al., 2003a) and that may
be the reason of a large overlap of
CTACK/CCL27 levels between healthy
controls and an early stage of CTCL
(Figure 1a). Serum CTACK/CCL27 le-
vels in patients with tumor were higher
than those in erythrodermic patients
probably because three out of five
patients with skin tumor had systemic
involvement. In addition, erythroder-
mic CTCL is very rare and the number
of cases may not be enough. Therefore,
further study with larger number of
patients would be useful to fully deter-
mine the potential usefulness of
CTACK/CCL27 levels as a treatment-
and diagnosis-related biomarker.
Previous reports showed that CCR10
is expressed in CTCL (Notohamiprodjo
et al., 2005) and that CCR10 engage-
ment by CTACK/CCL27 allows mela-
noma cells to escape host immune anti-
tumor killing mechanisms (Murakami
et al., 2003). The same pathway may be
involved when CTCL cells escape host
immunity. Our data suggest its possibi-
lity and that functional blocking of
CTACK/CCL27 would be another target
for treatment.
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The Receptor for Cis-Urocanic Acid Remains Elusive
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TO THE EDITOR
The number of human diseases in
which the immunomodulatory effects
of UV radiation play a role is expand-
ing, and include not only the develop-
ment of skin cancers but also
autoimmune and infectious diseases.
In addition, UV has long been recog-
nized as an important therapeutic for
the treatment of inflammatory skin
conditions. Molecules in skin that
absorb UV radiation include the DNA
and membrane lipids of epidermal
cells, as well as trans-urocanic acid
(trans-UCA), a major molecule of the
stratum corneum. On irradiation, it is
converted to the more soluble cis-
isomer. The action spectrum of UVB-
induced systemic suppression of con-
tact hypersensitivity responses in mice
closely follows the absorption spectrum
of UCA (De Fabo and Noonan, 1983).
Abbreviations: DOI, 2,5-dimethoxy-4-iodophenyl-2-aminopropane; 5-HT, 5-hydroxytryptamine;
LPS, lipopolysaccharide; PBMC, peripheral blood mononuclear cell; PGE2, prostaglandin E2;
TNF-a, tumor necrosis factor-alpha; UCA, urocanic acid
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Cis-UCA in UV-Induced Immunomodulation
